Cargando…

Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

Detalles Bibliográficos
Autores principales:	Ohki, Takamasa, Sato, Koki, Yamagami, Mari, Ito, Daisaku, Yamada, Tomoharu, Kawanishi, Koki, Kojima, Kentaro, Seki, Michiharu, Toda, Nobuo, Tagawa, Kazumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969905/ https://www.ncbi.nlm.nih.gov/pubmed/26728977 http://dx.doi.org/10.1007/s40261-015-0363-x

Ejemplares similares

Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
por: Ohki, Takamasa, et al.
Publicado: (2015)

Erratum to: Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
por: Ohki, Takamasa, et al.
Publicado: (2017)

Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
por: Ohki, Takamasa, et al.
Publicado: (2017)

Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium
por: Karasawa, Yuki, et al.
Publicado: (2021)

Risk factors of poor prognosis and impairment of activities of daily living in patients with hemorrhagic gastroduodenal ulcers
por: Arai, Junya, et al.
Publicado: (2021)

Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report
por: Kurokawa, Ken, et al.
Publicado: (2020)

Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report
por: Shibata, Chikako, et al.
Publicado: (2019)

Impact of the Sensitivity to Empiric Antibiotics on Clinical Outcomes after Biliary Drainage for Acute Cholangitis
por: Kawamura, Satoshi, et al.
Publicado: (2020)

Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib
por: Fu, Sirui, et al.
Publicado: (2016)

Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
por: NISHIKAWA, HIROKI, et al.
Publicado: (2012)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis
por: Cai, Rong, et al.
Publicado: (2017)

Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma
por: Huang, Yao-Kuang, et al.
Publicado: (2017)

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma
por: Kaibori, Masaki, et al.
Publicado: (2021)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)

Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma
por: Mawatari, Seiichi, et al.
Publicado: (2022)

Transcatheter Arterial Chemoembolization and Chemotherapy plus Sorafenib in a Large Hepatocellular Carcinoma with Arterioportal Shunt
por: Chen, Jun, et al.
Publicado: (2014)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion
por: Yang, Dan, et al.
Publicado: (2023)

Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial
por: Lee, Teng-Yu, et al.
Publicado: (2017)

Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019)

The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma
por: Su, Dongna
Publicado: (2021)

Erratum to: Sorafenib-Associated Facial Acneiform Eruption
por: Cohen, Philip R.
Publicado: (2015)

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials
por: Li, Jun, et al.
Publicado: (2017)

Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization
por: He, Kun, et al.
Publicado: (2022)

Transcatheter Arterial Chemoembolization Plus (131)I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Zhu, Ze-xin, et al.
Publicado: (2016)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
por: Lei, Xue-Fen, et al.
Publicado: (2018)

Efficacy of transcatheter arterial chemoembolization combined with sorafenib in inhibiting tumor angiogenesis in a rabbit VX2 liver cancer model
por: Li, WeiZhi, et al.
Publicado: (2020)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results: Erratum
Publicado: (2017)

Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GR
por: Yang, Wenjie, et al.
Publicado: (2018)

Erratum to “Durable Objective Response to Sorafenib and Role of Sequential Treatment in Unresectable Hepatocellular Carcinoma”
Publicado: (2022)

Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma
por: Yang, De-jun, et al.
Publicado: (2016)

Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma: Erratum
Publicado: (2015)

Cure of Hepatoblastoma Through Transcatheter Arterial Chemoembolization
por: Yang, Tianyou, et al.
Publicado: (2017)

Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization
por: Kobayashi, Saito, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rk8r0cm2lvfdnefgpc529nmnd1